<DOC>
	<DOCNO>NCT00397800</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Drugs use chemotherapy , fludarabine cyclophosphamide , work different way stop growth cancer cell , either kill cell stop dividing . Radiolabeled monoclonal antibody , yttrium Y 90 ibritumomab tiuxetan , find cancer cell carry cancer-killing substance without harm normal cell . Giving rituximab chemotherapy together yttrium Y 90 ibritumomab tiuxetan may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose yttrium Y 90 ibritumomab tiuxetan give together rituximab , fludarabine , cyclophosphamide see well work treat patient relapse B-cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab , Fludarabine , Cyclophosphamide , Yttrium Y 90 Ibritumomab Tiuxetan Treating Patients With Relapsed B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose rituximab yttrium Y 90 ( ^90Y ) ibritumomab tiuxetan administer rituximab radioimmunotherapy rituximab , fludarabine , cyclophosphamide patient relapse indolent , mantle cell , transform CD20-positive B-cell non-Hodgkin 's lymphoma . Secondary - Determine overall survival patient treat regimen . - Determine time progression event-free survival patient treat regimen . - Determine partial complete response rate patient treated regimen . - Determine time maximal response patient treat regimen . - Determine response duration patient treat regimen . - Determine feasibility additional antineoplastic treatment follow disease relapse treatment rituximab ^90Y ibritumomab tiuxetan patient . OUTLINE : This prospective , nonrandomized , multicenter , phase I dose-escalation study yttrium Y 90 ( ^90Y ) ibritumomab tiuxetan follow phase II open-label study . - Phase I : - Chemoimmunotherapy : Patients receive rituximab IV day 1 fludarabine IV 30 minute cyclophosphamide IV 60 minute day 1-3 . Treatment repeat every 4 week 3 course absence disease progression . Four week first day last chemoimmunotherapy course , patient receive 1 dose rituximab IV alone . Patients disease progression remove study . Patients stable disease proceed radioimmunotherapy 8-12 week first day last chemoimmunotherapy course . - Radioimmunotherapy : Patients receive rituximab IV image dose indium In III ibritumomab tiuxetan IV 10 minute day 1 . Patients undergo image . If dosimetry acceptable , patient receive rituximab IV ^90Y ibritumomab tiuxetan IV 10 minute day 8 . Cohorts 3-6 patient receive escalate dos ^90Y ibritumomab tiuxetan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Patients receive chemoimmunotherapy radioimmunotherapy phase I , MTD determine phase I . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 2 year . PROJECTED ACCRUAL : A total 12 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm CD20positive Bcell nonHodgkin 's lymphoma ( NHL ) , include follow subtypes : Indolent NHL , include follow : Follicular Lymphoplasmacytoid Marginal zone Mantle cell NHL Transformed Bcell NHL In least first relapse indication systemic antineoplastic treatment , define follow : Local constitutional ( B ) symptoms Hypersplenism due splenic involvement Bulky disease ( &gt; 7.5 cm diameter ) Impending medical problem derive rapid disease progression within past 6 month , define observe anticipated &gt; 50 % increase sum area calculate multiply great perpendicular diameter lesion Measurable lesion lymphoma infiltration Medically ineligible highdose treatment follow autologous stem cell support Adequate bone marrow cellularity ( &gt; 15 % marrow area cover hematopoiesis ) No CNS , leptomeningeal , spinal cord , testes lymphoma involvement No lymphoma lesion mandate emergency radiotherapy No clinical , cytological , cytogenetic , histopathologic indication myelodysplastic syndrome If bone marrow infiltration detect prior chemoimmunotherapy , patient must undergo repeat bone marrow biopsy prior plan treatment radioimmunotherapy verify level bone marrow infiltration &lt; 25 % PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 3 month Absolute neutrophil count &gt; 1,500/mm³ Platelet count &gt; 150,000/mm³ Hemoglobin &gt; 9 g/dL Creatinine &lt; 1.5 time upper limit normal ( ULN ) Bilirubin &lt; 2 time ULN ALT AST &lt; 2 time ULN Albumin &gt; 2.5 g/dL INR &lt; 1.5 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 12 month completion study treatment No concurrent severe and/or uncontrolled medical disease would preclude study compliance , include follow : Uncontrolled diabetes Congestive heart failure Chronic renal disease Active uncontrolled infection No bleeding risk disorder , include follow : CNS abnormalities suggest increase susceptibility hemorrhage , include recent history stroke demonstrate cranial contrastenhanced CT scan Severe arrhythmia uncontrolled hypertension Myocardial infarction within past 6 month Diabetic retinopathy history symptomatic hemorrhage Known potentially active gastrointestinal bleeding foci Concurrent anticoagulant medication must continue even platelet count &lt; 20,000/mm³ ( e.g. , follow mitral valve replacement , antiphospholipid syndrome , recurrent venous thromboembolism ) Other congenital acquire hemorrhagic diatheses No ongoing autoimmune hemolytic anemia No know presence antimurine antibody reactivity No known hypersensitivity murine chimeric antibody proteins No known HIV infection No psychiatric illness would preclude study requirement No malignant disorder within past 10 year except basal cell carcinoma skin carcinoma situ cervix PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No 4 prior systemic antilymphoma regimen ( include singleagent rituximab ) At least 2 month since prior systemic antilymphoma treatment ( include singleagent rituximab ) No prior radioimmunotherapy No prior autologous allogeneic hematopoietic stem cell transplantation No prior treatment purine analogue result remission &gt; 1 year No prior antiCD20 radioimmunoconjugate therapy More 5 year since prior radiotherapy extensive field cover lymph node region side diaphragm &gt; 50 % spinal column More 4 week since prior surgery No concurrent oral anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>